{"id":13004,"date":"2026-05-29T08:16:00","date_gmt":"2026-05-29T06:16:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=4f8e2e976bc36a28184750039efef9f0"},"modified":"2026-05-29T08:16:00","modified_gmt":"2026-05-29T06:16:00","slug":"zts-investors-have-opportunity-to-lead-zoetis-inc-securities-fraud-lawsuit-with-the-schall-law-firm","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=13004","title":{"rendered":"ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--$ZTS<\/a>--The Schall Law Firm<\/a>, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. (\u201cZoetis\u201d or \u201cthe Company\u201d) (NYSE: ZTS<\/a>) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.<\/p><\/a><\/a>

\nInvestors who purchased the Company\u2019s securities between January 14, 2025 and May 6, 2026, inclusive (the \u201cClass Period\u201d), are encouraged to contact the firm before July 27, 2026.<\/p>

\nIf you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>

\nWe also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com<\/a>, or by email at bschall@schallfirm.com<\/a>.<\/p>

\nThe class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.<\/p>

\nAccording to the Complaint, the Company made false and misleading statements to the market. Zoetis suffered from weakening veterinarian prescription growth for its Librela medication after the FDA issued safety warnings about neurological complications in dogs. The Company\u2019s Trio product lost market share to competitors. The Company\u2019s Apoquel and Cytopoint dermatology products lost market share to newly launched competing treatments for dogs. Based on these facts, the Company\u2019s public statements were false and materially misleading throughout the class period. When the market learned the truth about Zoetis, investors suffered damages.<\/p>

\nJoin the case<\/a> to recover your losses<\/p>

\nThe Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.<\/p>

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p> Contacts<\/b>

\nThe Schall Law Firm\nBrian Schall, Esq.,\nwww.schallfirm.com<\/a>Office: 310-301-3335\ninfo@schallfirm.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–$ZTS–The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. (\u201cZoetis\u201d or \u201cthe Company\u201d) (NYSE: ZTS) for violations of \u00a7\u00a710(b) and 20(a) of the S…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-13004","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13004"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13004\/revisions"}],"predecessor-version":[{"id":13005,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13004\/revisions\/13005"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}